Tamoxifen — Panacea or Pandora's Box?

Publisher Website
Google Scholar
Abstract
TAMOXIFEN, a nonsteroidal compound that has both antiestrogen and estrogen-agonist activity, has been used to treat women with breast cancer for nearly 20 years, and many clinical trials have documented its efficacy in the palliative care of patients with metastatic disease. Its use is associated with a significant reduction in the rates of disease recurrence and death among women over 50 years of age who have early-stage breast cancer, although its benefits in younger women are less well established. Moreover, the adjuvant use of tamoxifen may reduce the risk of cancer in the other breast.1 Data emerging from trials of . . .